+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Clinical results of pharmacokinetic modulating chemotherapy (PMC) in combination with hepatic arterial 5FU infusion, continuous venous 5FU infusion and oral UFT as adjuvant chemotherapy after liver resection for hepatic colorectal metastases



Clinical results of pharmacokinetic modulating chemotherapy (PMC) in combination with hepatic arterial 5FU infusion, continuous venous 5FU infusion and oral UFT as adjuvant chemotherapy after liver resection for hepatic colorectal metastases



Journal of Clinical Oncology 23(16_Suppl): 3665-3665



NlmCategory="UNASSIGNED">3665 Background: We have presented the usefulness of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5FU infusion and oral UFT (HAI-PMC) as adjuvant chemotherapy after liver resection for hepatic colorectal metastases before. (ASCO Abst 556,2001) We also assessed the usefulness of PMC in combination with continuous venous 5FU infusion and oral UFT (CVI-PMC) as adjuvant chemotherapy for Dukes C colorectal cancer. (ASCO Abst 1175,2003) To decrease the recurrent rate at extrahepatic sites and improve prognosis we instituted PMC in combination with hepatic arterial 5FU infusion, continuous venous 5FU infusion and oral UFT as adjuvant chemotherapy after liver resection for hepatic colorectal metastases. Fifty-nine patients were randomly divided into 2 groups after liver resection. Group A (n=30 patients), underwent HAI-PMC in a combination of intra-arterial infusion of 5FU for 2 consecutive days per week at 600mg/m2/day and oral administration of UFT at 400mg/day for 5 days per week for 3 months. Group B (n=29), underwent CVI-PMC in a combination of continuous venous 5FU infusion per week at 600mg/m2/day and oral administration of UFT at 400mg/day for 5 to 7 days per week for 12 months after finishing HAI-PMC. The five-year survival rate of patients in the A group was 61%, and in the B group 63%.(p=0.98) The five-year recurrence rate in remnant liver after hepatic resection was 12% and 11%, respectively (p=0.82); and the rate of extrahepatic recurrence was 38.1% and 34.6%, respectively (P-0.56). It is thought that further intensive systemic chemotherapy is necessary to decrease the rate of extrahepatic recurrence and improve prognosis. No significant financial relationships to disclose.

(PDF emailed within 1 workday: $29.90)

Accession: 057425654

Download citation: RISBibTeXText

PMID: 27944887


Related references

Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases. Cancer 89(6): 1228-1235, September 15, 2000

Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy. Annals of Surgery 257(1): 114-120, 2013

Treatment of liver metastases from colorectal cancer--major hepatic resection and continuous hepatic arterial infusion chemotherapy. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 17(4 Pt 2): 777-781, 1990

Efficacy of adjuvant hepatic arterial infusion chemotherapy following resection of colorectal liver metastases. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 26(12): 1698-1701, 1999

Adjuvant hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases. American Journal of Surgery 166(6): 743-6; Discussion 746-8, 1993

Evaluation of continuous intra-arterial infusion chemotherapy after hepatic resection of liver metastases in colorectal cancer. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 18(11): 1935-1939, 1991

Prophylactic adjuvant hepatic arterial infusion chemotherapy reduced hepatic metastases from Stage III colorectal cancer after curative resection. Hepato-Gastroenterology 59(116): 1087-1090, 2012

Feasibility of adjuvant hepatic arterial infusion of chemotherapy after radiofrequency ablation with or without resection in patients with hepatic metastases from colorectal cancer. Annals of Surgical Oncology 10(4): 348-354, 2003

A pilot study of adjuvant hepatic arterial infusion chemotherapy, associating 5-fluorouracil and leucovorin, after resection of colorectal cancer liver metastases. Surgical Oncology 4(6): 317-322, 1995

Evaluation of hepatic resection following hepatic arterial infusion chemotherapy for colorectal liver metastases. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 27(12): 1826-1829, 2000

Study of hepatic arterial infusion chemotherapy for prophylaxis of liver metastases of colorectal cancer after hepatic resection. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 22(11): 1497-1499, 1995

Indication for hepatic resection after hepatic arterial infusion chemotherapy for multiple liver metastases of colorectal cancer. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 27(12): 1834-1837, 2000

Indication of prophylactic hepatic arterial-infusion chemotherapy after hepatic resection for liver metastases from colorectal cancer. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 23(11): 1457-1460, 1996

Results of preoperative hepatic arterial infusion chemotherapy in patients undergoing liver resection for colorectal liver metastases. Annals of Surgical Oncology 15(6): 1661-1669, 2008

Intermittent hepatic arterial infusion of high-dose fluorouracil on a weekly schedule as adjuvant chemotherapy following curative resection of colorectal liver metastases: a randomized study. Journal of Clinical Oncology 23(16_Suppl): 3727-3727, 2016